Psyence Biomedical Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Phase IIb Clinical Trial Patient Enrollment QuarterlyTarget: 87 participants
Active Clinical Trial Sites Quarterly5.0Target: 5 sites
Cash and Cash Equivalents Quarterly7.5M
Watch Items
- Topline results release for Phase IIb psilocybin trial evaluating NPX-5 for Adjustment Disorder in palliative careTrigger: Release of clinical efficacy and safety dataAction: Evaluate therapeutic efficacy of NPX-5 against low-dose comparator and assess regulatory pathway viability with FDA/HREC
- U.S. Executive Action and Policy on Ibogaine ResearchTrigger: Signing or implementation of the prepared U.S. executive order evaluating ibogaine safety and therapeutic potentialAction: Leverage GMP-compliant ibogaine supply chain and manufacturing capabilities via PsyLabs to support U.S. clinical research
- Nasdaq Listing Compliance and Share PriceTrigger: Share price falling below Nasdaq minimum bid price requirementsAction: Monitor execution of the 2026 Financial Strategy and Capital Management Framework, including potential share repurchases
Research as of 20 Jun 2026